Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 16, 2026

Most Americans Think Medicare Covers More Than It Does: A 2025 Study Shows Only 26% Have It Right

View original at finance.yahoo.com
“Medicare transfer receipts to households jumped from $1,172.6 billion in Q1 2025 to $1,301 billion in Q1 2026.”
Verbatim excerpt from the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Medicare transfer receipts to households jumped from $1,172.6 billion in Q1 2025 to $1,301 billion in Q1 2026, but the share covered per beneficiary remains static.

    60% confidence
  • Services inflation remains stubbornly above 3% annually.

    60% confidence
  • U.S. personal savings rates have fallen to 4%, contributing to a cash flow crisis for retirees unaware of Medicare's actual coverage limits.

    60% confidence
  • Medicare covers roughly two-thirds of retiree healthcare costs, leaving the rest to premiums, copays, deductibles, prescriptions, dental, vision, hearing, and long-term care.

    60% confidence
  • Medicare does not pay for long-term care in any extended form.

    60% confidence
  • Healthcare has surged to become the second-largest services spending category in the U.S. economy at $3,741.3 billion as of March 2026, accounting for roughly 24.8% of all services spending.

    60% confidence
  • A 65-year-old retiring today could spend roughly $172,500 on healthcare over the course of retirement, per person and excluding long-term care.

    60% confidence
  • 74% of Americans either overestimated Medicare's coverage or admitted they did not know how much it covers, representing a material planning risk for millions of household budgets.

    60% confidence
  • Only 26% of U.S. adults correctly understand that Medicare covers approximately two-thirds of retiree healthcare costs.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com